Skip to main content

Table 3 Change of clinical parameters after admission

From: A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time

Parameters

Units

In hospital

After discharge

Under dosing tamoxifen

7 days after tamoxifen withdrawal

2 months after dosing pemafibrate

Parameters related with lipid metabolism

 TC

mg/dL

341

282

234

 TG

mg/dL

964

675

231

 HDL-C

mg/dL

34

33

46

 LDL-C

mg/dL

68

114

156

 non-HDL-C

mg/dL

307

249

188

 RLP-C

mg/dL

59.0

11.3

 Apo A-I

mg/dL

148

 

153

 Apo B

mg/dL

158

155

142

 Apo C-II

mg/dL

21.8

14.5

9.5

 Apo C-III

mg/dL

63.4

33.9

20.0

 Apo C-III/C-II ratio

 

2.9

2.3

2.1

 Apo E

mg/dL

14.7

 

5.5

 LDL-C/ Apo B ratio

 

0.51

0.73

1.10

Lipoprotein fraction test (PAGE method)

 HDL

%

18

10

17

 BAND 1

%

4

16

 

 LDL

%

16

12

44

 MIDBAND

%

39

35

24

 VLDL

%

23

27

15

 LDL-MI

 

0.67

0.60

0.37

Other parameters

 HbA1c

%

7.3

7.0

 Cre

mg/dL

1.40

 

1.00

 eGFR

ml/min/1.75m2

32.9

 

47.5

 P-Amy

U/L

72

53

  1. TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein- cholesterol, LDL-C low density lipoprotein- cholesterol, RLP-C remnant lipoprotein- cholesterol, Apo apolipoprotein, PAGE polyacrylamide gel electrophoresis, LDL-MI LDL-migration index, Cre creatinine, eGFR estimated glomerular filtration rate, P-Amy pancreatic amylase. LDL size was assessed by the migration of the LDL fraction, and LDL-MI was identified by the migration distance of LDL fraction relative to the HDL fraction